Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease

被引:277
作者
Walkley, Carl R. [1 ,2 ]
Qudsi, Rameez [1 ,2 ]
Sankaran, Vijay G. [1 ,2 ]
Perry, Jennifer A. [1 ,2 ]
Gostissa, Monica [3 ,4 ]
Roth, Sanford I. [5 ]
Rodda, Stephen J. [6 ]
Snay, Erin [7 ]
Dunning, Patricia [8 ]
Fahey, Frederic H. [7 ]
Alt, Frederick W. [3 ,4 ]
McMahon, Andrew P. [6 ]
Orkin, Stuart H. [1 ,2 ,9 ]
机构
[1] Harvard Univ, Sch Med,Harvard Stem Cell Inst, Dept Pediat Oncol,Childrens Hosp, Dana Farber Canc Inst,Div Hematol Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Stem Cell Program, Childrens Hosp,Harvard Stem Cell Inst, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Genet, Boston, MA 02115 USA
[4] Immune Dis Inst, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
[7] Harvard Univ, Sch Med, Div Nucl Med, Childrens Hosp, Boston, MA 02115 USA
[8] Harvard Univ, Sch Med, Dept Radiol, Childrens Hosp, Boston, MA 02115 USA
[9] Howard Hughes Med Inst, Boston, MA 02115 USA
关键词
cancer; mouse model; osteocarcinoma;
D O I
10.1101/gad.1656808
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Osteosarcoma is the most common primary malignant tumor of bone. Analysis of familial cancer syndromes and sporadic cases has strongly implicated both p53 and pRb in its pathogenesis; however, the relative contribution of these mutations to the initiation of osteosarcoma is unclear. We describe here the generation and characterization of a genetically engineered mouse model in which all animals develop short latency malignant osteosarcoma. The genetically engineered mouse model is based on osteoblast-restricted deletion of p53 and pRb. Osteosarcoma development is dependent on loss of p53 and potentiated by loss of pRb, revealing a dominance of p53 mutation in the development of osteosarcoma. The model reproduces many of the defining features of human osteosarcoma including cytogenetic complexity and comparable gene expression signatures, histology, and metastatic behavior. Using a novel in silico methodology termed cytogenetic region enrichment analysis, we demonstrate high conservation of gene expression changes between murine osteosarcoma and known cytogentically rearranged loci from human osteosarcoma. Due to the strong similarity between murine osteosarcoma and human osteosarcoma in this model, this should provide a valuable platform for addressing the molecular genetics of osteosarcoma and for developing novel therapeutic strategies.
引用
收藏
页码:1662 / 1676
页数:15
相关论文
共 81 条
[41]   Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system [J].
MacPherson, D ;
Sage, J ;
Crowley, D ;
Trumpp, A ;
Bronson, RT ;
Jacks, T .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (03) :1044-1053
[42]   Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors [J].
McClatchey, AI ;
Saotome, I ;
Mercer, K ;
Crowley, D ;
Gusella, JF ;
Bronson, RT ;
Jacks, T .
GENES & DEVELOPMENT, 1998, 12 (08) :1121-1133
[43]   Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes [J].
Mendoza, S ;
David, H ;
Gaylord, GM ;
Miller, CW .
CANCER GENETICS AND CYTOGENETICS, 2005, 158 (02) :142-147
[44]   Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate [J].
Meyers, PA ;
Schwartz, CL ;
Krailo, M ;
Kleinerman, ES ;
Betcher, D ;
Bernstein, ML ;
Conrad, E ;
Ferguson, W ;
Gebhardt, M ;
Goorin, AM ;
Harris, MB ;
Healey, J ;
Huvos, A ;
Link, M ;
Montebello, J ;
Nadel, H ;
Nieder, M ;
Sato, J ;
Siegal, G ;
Weiner, M ;
Wells, R ;
Wold, L ;
Womer, R ;
Grier, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :2004-2011
[45]   RETROSPECTIVE REVIEW OF NEOADJUVANT CHEMOTHERAPY FOR OSTEOGENIC-SARCOMA [J].
MEYERS, PA ;
HELLER, G ;
HEALEY, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (03) :202-203
[46]  
MILLER CW, 1990, CANCER RES, V50, P7950
[47]   The p19(INK4D) Cyclin dependent kinase inhibitor gene is altered in osteosarcoma [J].
Miller, CW ;
Yeon, C ;
Aslo, A ;
Mendoza, S ;
Aytac, U ;
Koeffler, HP .
ONCOGENE, 1997, 15 (02) :231-235
[48]   Alterations of the p15, p16, and p18 genes in osteosarcoma [J].
Miller, CW ;
Aslo, A ;
Campbell, MJ ;
Kawamata, N ;
Lampkin, BC ;
Koeffler, HP .
CANCER GENETICS AND CYTOGENETICS, 1996, 86 (02) :136-142
[49]   PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes [J].
Mootha, VK ;
Lindgren, CM ;
Eriksson, KF ;
Subramanian, A ;
Sihag, S ;
Lehar, J ;
Puigserver, P ;
Carlsson, E ;
Ridderstråle, M ;
Laurila, E ;
Houstis, N ;
Daly, MJ ;
Patterson, N ;
Mesirov, JP ;
Golub, TR ;
Tamayo, P ;
Spiegelman, B ;
Lander, ES ;
Hirschhorn, JN ;
Altshuler, D ;
Groop, LC .
NATURE GENETICS, 2003, 34 (03) :267-273
[50]  
Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5